Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome

scientific article published on June 1999

Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1046/J.1365-2133.1999.02889.X
P8608Fatcat IDrelease_wgsyuusvxjh5ba4jvnmwlgsg3i
P698PubMed publication ID10354086

P2093author name stringBurg G
Nestle FO
Dummer R
Kleinhans M
Fritz TM
P2860cites workTreatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary resultsQ28300282
Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).Q34333859
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoidesQ40768413
The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomasQ40809016
Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institutionQ41262862
Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone.Q50868440
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectinterferon alfaQ6046441
P304page(s)1144-1147
P577publication date1999-06-01
P1433published inBritish Journal of DermatologyQ4970191
P1476titleCombination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome
P478volume140

Reverse relations

cites work (P2860)
Q37944565Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management
Q27024076Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management
Q36470196Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management
Q48034709Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
Q35622833Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.
Q38010239Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art.
Q34560665Immunomodulators in the treatment of cutaneous lymphomas
Q35612026Interferon in the treatment of cutaneous T-cell lymphoma
Q35622819Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow
Q33625948The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society
Q37954015The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas
Q35612038The treatment of cutaneous T-cell lymphoma with photopheresis
Q34547470Therapy for mycosis fungoides
Q37074253U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease
Q84471693[Extracorporeal photopheresis in dermatology]